Analgesia After ED Discharge for Extremity Injuries
Conditions
Keywords
Pain Management, Emergency Medicine, Extremity Injuries
Brief summary
There will be 3 randomized, double-blinded clinical trials to help determine which of commonly prescribed oral opioid combination is most effective in managing acute extremity pain after discharge from the adult emergency department. The first trial compares hydrocodone 5mg / acetaminophen 500mg to codeine 30mg/acetaminophen 300mg. The second trial compares oxycodone 5mg/acetaminophen 325mg to codeine 30mg/acetaminophen 300mg. The third trial compares oxycodone 5mg/acetaminophen 325 mg to hydrocodone 5mg/acetaminophen 325 mg.
Detailed description
Eligible patients are those between the ages of 21 and 64 who present to the Emergency Department (ED) with a complaint of acute extremity pain of less than seven days duration in one or more extremities and for whom the clinician plans to discharge on an oral opioid for pain management. Patients will be excluded if they have ever taken methadone; have a chronic condition requiring frequent pain management such as sickle cell disease, fibromyalgia, or any neuropathy; report a history of an adverse reaction to any of the study medications; if they have taken prescribed opioids in the past 24 hours or if they report having ever taken recreational narcotics; if they have a medical condition that might affect their metabolism of opioid analgesics or acetaminophen; or if they take any medicine that might interact with one of the study medications. Patients will be referred by the attending physician or clinician and consent as well as the initial and follow-up data collections will be obtained by our team of trained bilingual (Spanish and English) salaried research associates who staff the ED 24 hours a day and 7 days a week. In the first study, patients will be randomized to one of two experimental groups: hydrocodone 5mg / acetaminophen 500mg or codeine 30mg / acetaminophen 300mg. Randomization will be performed in blocks of 10 and determined by a sequence generated at http://www.randomization.com. The pharmacist working in an area inaccessible to ED staff will ensure proper blinding of the study by masking the medication and inserting it into unmarked gel capsules and filling any void with small amounts of lactose. A three-day supply (18 doses) of the blinded medications will be dispensed by the ED staff to the patient in the order determined by randomization accompanied by instructions to use one tablet of the medication every 4 hours as needed for pain and to avoid use of any other analgesics. Using a power of 80%, a significance criterion of 0.5, and an estimated delta of 1.3 NRS units, a sample size of 85 patients per group. In order to account for those that do not end up taking the medicine, it is estimated that 120 patients per group will have to be enrolled. Data will be collected on a standardized data collection instrument, entered by a trained data clerk, and reviewed and audited for accuracy and completeness. The investigators will calculate descriptive statistics for all variables: frequencies, means and standard deviations, medians and IQR, and proportions. Chi-square tests will be used to test differences between dichotomous variables, t-tests will be used to test mean differences. Multivariate models will be used if there are background variables that are unevenly distributed between the two groups. Variables associated with group membership with probability of 0.20 or less will be included in OLS multivariate regression or logistic regression models in order to test the role of group membership while accounting for chance baseline disparities. Interaction terms will be tested and dropped from the models if they were not statically significant at the 0.05 level. SPSS version 17 (Chicago, IL.) will be used to conduct all data analyses. The second trial will be identical to the first trial with the exception of one of the study drugs, which will be oxycodone 5mg / acetaminophen 325 mg which will be compared to codeine 30mg / acetaminophen 300mg. The third trial will be identical to the first and second trials with the exception of study drugs. This study will use oxycodone 5 mg/acetaminophen 325mg and hydrocodone 5mg/acetaminophen 325mg.
Interventions
Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
Sponsors
Study design
Eligibility
Inclusion criteria
* patient has complaint of acute extremity pain (less than 7 days duration) * clinician plans to discharge on oral pain medication
Exclusion criteria
* patients on methadone * chronic pain condition such as sickle cell anemia or fibromyalgia * history of adverse reaction to one of the study medications * taken prescribed opioids in the past 24 hrs * have a medical condition that might alter the metabolism of one of the study medications (i.e. hepatitis, renal insufficiency, thyroid disease, Adrenal disease) * Take a medication that might interact with one of the study medications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in Pain Intensity Score Before and After Last Dose. | 2 hrs | Pain intensity is measured on the numerical rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable). The difference in pain score is calculated by subtracting the average score 2 hours after pain medication is taken from the average pain score immediately before the pain medication is taken. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Satisfaction With the Pain Medicine | 24 hrs | Overall satisfaction with the oral opioid pain medication at 24 hours after discharge using a Likert scale. Patients will be asked to describe their overall experience as being very satisfied, satisfied, unsatisfied or very unsatisfied with the study medication. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Hydrocodone (First Trial) Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
Hydrocodone (first trial): Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain | 88 |
| Codeine (First Trial) Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
Codeine (first trial): Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain | 93 |
| Oxycodone (for Second Trial) Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
Oxycodone (for second trial): Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain | 111 |
| Codeine (for Second Trial) Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
Codeine (for second trial): Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain | 104 |
| Oxycodone (Third Trial) Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
Oxycodone (third trial): Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain | 107 |
| Hydrocodone (Third Trial) Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
Hydrocodone (third trial): Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain. | 113 |
| Total | 616 |
Baseline characteristics
| Characteristic | Codeine (First Trial) | Total | Hydrocodone (First Trial) | Hydrocodone (Third Trial) | Oxycodone (Third Trial) | Codeine (for Second Trial) | Oxycodone (for Second Trial) |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 37 years STANDARD_DEVIATION 11 | 38 years STANDARD_DEVIATION 12 | 34 years STANDARD_DEVIATION 12 | 38 years STANDARD_DEVIATION 13 | 39 years STANDARD_DEVIATION 12 | 38 years STANDARD_DEVIATION 11 | 39 years STANDARD_DEVIATION 12 |
| Diagnosis Extremity Fracture | 17 Participants | 228 Participants | 20 Participants | 58 Participants | 63 Participants | 37 Participants | 33 Participants |
| Diagnosis Other | 22 Participants | 105 Participants | 28 Participants | 13 Participants | 5 Participants | 18 Participants | 19 Participants |
| Diagnosis Sprain/strain | 54 Participants | 283 Participants | 40 Participants | 42 Participants | 39 Participants | 49 Participants | 59 Participants |
| NRS pain intensity score on discharge | 7 units on a scale | 7 units on a scale | 7 units on a scale | 8 units on a scale | 8 units on a scale | 7 units on a scale | 7 units on a scale |
| NRS pain intensity score on ED arrival | 9 units on a scale | 10 units on a scale | 9 units on a scale | 10 units on a scale | 10 units on a scale | 10 units on a scale | 10 units on a scale |
| Race/Ethnicity, Customized African American | 18 Participants | 167 Participants | 27 Participants | 28 Participants | 32 Participants | 27 Participants | 35 Participants |
| Race/Ethnicity, Customized Hispanic | 69 Participants | 402 Participants | 56 Participants | 73 Participants | 67 Participants | 71 Participants | 66 Participants |
| Race/Ethnicity, Customized Other | 6 Participants | 47 Participants | 5 Participants | 12 Participants | 8 Participants | 6 Participants | 10 Participants |
| Region of Enrollment United States | 93 Participants | 616 Participants | 88 Participants | 113 Participants | 107 Participants | 104 Participants | 111 Participants |
| Sex: Female, Male Female | 48 Participants | 314 Participants | 38 Participants | 48 Participants | 60 Participants | 58 Participants | 62 Participants |
| Sex: Female, Male Male | 45 Participants | 302 Participants | 50 Participants | 65 Participants | 47 Participants | 46 Participants | 49 Participants |
| Took analgesic prior to presentation No | 63 Participants | 418 Participants | 63 Participants | 74 Participants | 76 Participants | 70 Participants | 72 Participants |
| Took analgesic prior to presentation Unknown | 3 Participants | 12 Participants | 1 Participants | 3 Participants | 2 Participants | 1 Participants | 2 Participants |
| Took analgesic prior to presentation Yes | 27 Participants | 186 Participants | 24 Participants | 36 Participants | 29 Participants | 33 Participants | 37 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 88 | 0 / 93 | 0 / 111 | 0 / 104 | 0 / 107 | 0 / 113 |
| other Total, other adverse events | 54 / 88 | 51 / 93 | 68 / 111 | 61 / 104 | 74 / 106 | 51 / 112 |
| serious Total, serious adverse events | 0 / 88 | 0 / 93 | 0 / 111 | 0 / 104 | 0 / 107 | 0 / 113 |
Outcome results
Difference in Pain Intensity Score Before and After Last Dose.
Pain intensity is measured on the numerical rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable). The difference in pain score is calculated by subtracting the average score 2 hours after pain medication is taken from the average pain score immediately before the pain medication is taken.
Time frame: 2 hrs
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Hydrocodone (First Trial) | Difference in Pain Intensity Score Before and After Last Dose. | 2 hours after most recent dose | 3.6 units on a scale | Standard Deviation 2.8 |
| Hydrocodone (First Trial) | Difference in Pain Intensity Score Before and After Last Dose. | before most recent dose | 7.6 units on a scale | Standard Deviation 1.7 |
| Hydrocodone (First Trial) | Difference in Pain Intensity Score Before and After Last Dose. | change in NRS before to after most recent dose | 3.9 units on a scale | Standard Deviation 2.5 |
| Codeine (First Trial) | Difference in Pain Intensity Score Before and After Last Dose. | 2 hours after most recent dose | 4.1 units on a scale | Standard Deviation 2.9 |
| Codeine (First Trial) | Difference in Pain Intensity Score Before and After Last Dose. | before most recent dose | 7.6 units on a scale | Standard Deviation 1.8 |
| Codeine (First Trial) | Difference in Pain Intensity Score Before and After Last Dose. | change in NRS before to after most recent dose | 3.5 units on a scale | Standard Deviation 2.6 |
| Oxycodone (for Second Trial) | Difference in Pain Intensity Score Before and After Last Dose. | 2 hours after most recent dose | 3.4 units on a scale | Standard Deviation 2.5 |
| Oxycodone (for Second Trial) | Difference in Pain Intensity Score Before and After Last Dose. | before most recent dose | 7.9 units on a scale | Standard Deviation 1.5 |
| Oxycodone (for Second Trial) | Difference in Pain Intensity Score Before and After Last Dose. | change in NRS before to after most recent dose | 4.5 units on a scale | Standard Deviation 2.4 |
| Codeine (for Second Trial) | Difference in Pain Intensity Score Before and After Last Dose. | 2 hours after most recent dose | 3.6 units on a scale | Standard Deviation 4.2 |
| Codeine (for Second Trial) | Difference in Pain Intensity Score Before and After Last Dose. | before most recent dose | 7.9 units on a scale | Standard Deviation 1.7 |
| Codeine (for Second Trial) | Difference in Pain Intensity Score Before and After Last Dose. | change in NRS before to after most recent dose | 4.2 units on a scale | Standard Deviation 2.4 |
| Oxycodone (Third Trial) | Difference in Pain Intensity Score Before and After Last Dose. | 2 hours after most recent dose | 3.3 units on a scale | Standard Deviation 2.7 |
| Oxycodone (Third Trial) | Difference in Pain Intensity Score Before and After Last Dose. | before most recent dose | 7.8 units on a scale | Standard Deviation 1.5 |
| Oxycodone (Third Trial) | Difference in Pain Intensity Score Before and After Last Dose. | change in NRS before to after most recent dose | 4.4 units on a scale | Standard Deviation 2.5 |
| Hydrocodone (Third Trial) | Difference in Pain Intensity Score Before and After Last Dose. | before most recent dose | 7.6 units on a scale | Standard Deviation 1.6 |
| Hydrocodone (Third Trial) | Difference in Pain Intensity Score Before and After Last Dose. | change in NRS before to after most recent dose | 4.0 units on a scale | Standard Deviation 2.5 |
| Hydrocodone (Third Trial) | Difference in Pain Intensity Score Before and After Last Dose. | 2 hours after most recent dose | 3.6 units on a scale | Standard Deviation 2.6 |
Overall Satisfaction With the Pain Medicine
Overall satisfaction with the oral opioid pain medication at 24 hours after discharge using a Likert scale. Patients will be asked to describe their overall experience as being very satisfied, satisfied, unsatisfied or very unsatisfied with the study medication.
Time frame: 24 hrs
Population: Any number analyzed that does not equal the overall number of participants is due to missing data
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Hydrocodone (First Trial) | Overall Satisfaction With the Pain Medicine | Number of participants satisfied with analgesic | 72 Participants |
| Hydrocodone (First Trial) | Overall Satisfaction With the Pain Medicine | participants would want the same analgesic again | 59 Participants |
| Codeine (First Trial) | Overall Satisfaction With the Pain Medicine | Number of participants satisfied with analgesic | 66 Participants |
| Codeine (First Trial) | Overall Satisfaction With the Pain Medicine | participants would want the same analgesic again | 66 Participants |
| Oxycodone (for Second Trial) | Overall Satisfaction With the Pain Medicine | Number of participants satisfied with analgesic | 99 Participants |
| Oxycodone (for Second Trial) | Overall Satisfaction With the Pain Medicine | participants would want the same analgesic again | 91 Participants |
| Codeine (for Second Trial) | Overall Satisfaction With the Pain Medicine | Number of participants satisfied with analgesic | 91 Participants |
| Codeine (for Second Trial) | Overall Satisfaction With the Pain Medicine | participants would want the same analgesic again | 85 Participants |
| Oxycodone (Third Trial) | Overall Satisfaction With the Pain Medicine | Number of participants satisfied with analgesic | 93 Participants |
| Oxycodone (Third Trial) | Overall Satisfaction With the Pain Medicine | participants would want the same analgesic again | 86 Participants |
| Hydrocodone (Third Trial) | Overall Satisfaction With the Pain Medicine | Number of participants satisfied with analgesic | 97 Participants |
| Hydrocodone (Third Trial) | Overall Satisfaction With the Pain Medicine | participants would want the same analgesic again | 90 Participants |
50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score
Time frame: 2 hours
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Hydrocodone (First Trial) | 50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score | 50 Participants |
| Codeine (First Trial) | 50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score | 45 Participants |
| Oxycodone (for Second Trial) | 50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score | 73 Participants |
| Codeine (for Second Trial) | 50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score | 64 Participants |
| Oxycodone (Third Trial) | 50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score | 68 Participants |
| Hydrocodone (Third Trial) | 50% or Greater Decrease in Numerical Rating Scale (NRS) Pain Score | 66 Participants |
Time to Follow up
Median time to contact patients for data collection, measured from discharge to time contacted
Time frame: up to 48 hours
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Hydrocodone (First Trial) | Time to Follow up | 27 hours |
| Codeine (First Trial) | Time to Follow up | 25 hours |
| Oxycodone (for Second Trial) | Time to Follow up | 26 hours |
| Codeine (for Second Trial) | Time to Follow up | 28 hours |
| Oxycodone (Third Trial) | Time to Follow up | 27 hours |
| Hydrocodone (Third Trial) | Time to Follow up | 28 hours |